Press Room

Press Clipping / Feb 13, 2025

The Secret to Being a Good Employer

The Medicine Maker, 13 February 2026

Why you shouldn’t neglect the importance of blending people, culture, and strategy to foster success in a business.

People, customer centricity, and a clear strategy bring strong values to the forefront of every business. Fostering a workplace that inspires motivation and enhances employee satisfaction enables team members to bring their best selves to work each day, driving innovation and excellence.

Earlier this year, CDMO Hovione demonstrated success by being certified as a Top Employer by the Top Employers Institute (TEI) across all four of its global manufacturing sites in Portugal, Ireland, the US, and Macau, for the third consecutive year. We spoke to board member and Senior Vice-President of Human Resources at Hovione Ilda Ventura to find out how.

What specific strategies and initiatives have you implemented to maintain the company’s Top Employer status?
 
We started the latest TEI Certification in 2023. Since then, we have been focusing on areas that can differentiate us as employers. In the US, for example, we have invested in bringing more proximity to the HR team, improving our listening strategy and the employee experience. The initiatives span from establishing better alignment between the business strategy and the people strategy, living our values and celebrating our successes. We are accelerating our global growth while strengthening our operations worldwide. It is essential for us to ensure that all our employees, regardless of their location, enjoy a consistent and unified work experience. Having all four of our sites recognized by TEI confirms that we are on the right path.

What changes have been made to Hovione's recognition and rewards programs to motivate employees?
 
By implementing a global job architecture with clear career roadmaps supported by a performance and compensation annual cycle. Everyone is eligible to merit remuneration increases and bonuses, and the corporate results are shared with everyone in a transparent way. This allows us to create a culture of recognition, where individual contributions are valued and aligned with the company's overall success. It fosters motivation and engagement, ensuring employees feel appreciated for their efforts and understand how their work directly aligns with our purpose. This culture not only enhances employee satisfaction, but strengthens our ability to attract and retain top talent. 

How important is it to monitor consistent employee engagement and satisfaction across global locations?
 
Our employee engagement survey results are carefully reviewed and discussed both locally and globally, ensuring we address the unique needs of each region while driving company-wide progress. We prioritize actionable improvements that resonate with our teams, engaging cross-functional and geographically diverse groups to implement meaningful change. 

Across our sites, we’ve made significant investments tailored to each region while maintaining a unified approach to employee satisfaction. In the US, where employees value transparency, recognition, and growth opportunities, we’ve enhanced communication, feedback channels, and career development pathways. Similarly, in Portugal, Ireland, and Macau, we’ve introduced initiatives to promote collaboration, recognition, and personal growth, ensuring all employees experience a sense of belonging and purpose. 

The actions we take are closely monitored, and every improvement is shared openly across all locations, fostering a culture of trust, transparency, and celebration that connects and empowers our workforce. 

How are you working to attract and retain top talent in the competitive pharma industry?
 
We continuously strive to strengthen our reputation as an employer of choice. Participating in TEI allows us to have an independent assessment of our HR efforts and initiatives, ensuring that we are continuously improving and aligning with best practices. In addition, we have robust referral programs in place, supported by the fact that over 70 percent of our employees are strong promoters of the company. This is a testament to the positive culture we’ve built, and we are focused on leveraging this strength to attract and retain top talent. 

In what ways does the company communicate and reinforce its core purpose and values among employees?
 
Our motto is “In it for life” – so, for example, every year we celebrate in each site our “Victory Over Diseases” by communicating the new products that we are manufacturing, as well as the new patents and innovative ideas that contribute to fighting diseases and improving global health. Contributing to saving the lives of billions of people worldwide is a way to motivate our people to challenge themselves and push the limits of innovation. By celebrating our achievements and their impact, we inspire our teams to think creatively, embrace new challenges, and contribute to solutions that make a real difference in the world. It´s an invitation to live our purpose. 

Macau was the first site in the region to earn Top Employer certification last year and has renewed it this year. What unique challenges and successes have been experienced in achieving and maintaining this status in Macau?
 
Macau is unique. It’s the only site in this industry in the territory, so we have taken advantage of that to differentiate ourselves as an employer by collaborating with universities and local authorities to offer career opportunities and benefits that are a reference in the region. 

What areas have you identified for continuous improvement in workplace practices and employee satisfaction in the future?
 
We will continue to strengthen our employee value proposition by mapping the employee journey and addressing every touchpoint to enhance the overall experience. Both people and business needs are constantly changing. It requires continuous adaptation of processes to meet evolving expectations. If I had to highlight one key focus, it would be alumni engagement. The Hovione community is extensive and goes beyond our current team members. We see a clear opportunity to create an alumni program to stay connected with those who have been part of our journey. 

 

Read the full article on themedicinemaker.com

 

 

Also in the Press Room

See All

Key Takeaways Commissioning a US-based ConsiGma CDC Flex line enables end-to-end spray drying-to-tablet manufacture within a single site and quality system, reducing comparability and technology-transfer burdens. Elimination of conventional scale-up is enabled by using the same equipment from early development through commercial supply, minimizing engineering runs and conserving scarce API. Operational flexibility spans batch or continuous modes and 1–200 kg/h throughput, with scale adjustment achieved by switching continuous blenders rather than replatforming processes. High-containment design to 1 µg/m³ expands suitability for highly potent oral solid-dose programs while maintaining integrated development-to-commercial workflows. Regulatory momentum for continuous manufacturing is supported by ICH Q13 harmonization, increasing FDA approvals, and platforms leveraging inline PAT and automated control suites for real-time quality assurance. Hovione announced on Oct. 5, 2026, that it will commission the ConsiGma CDC Flex, a next-generation continuous direct compression tableting platform jointly developed with GEA. The investment is designed to link amorphous solid dispersion manufacturing via spray drying with commercial tablet production at a single US site operating under one quality system. The line will run in either continuous or batch mode at throughputs from 1 to 200 kg/h. Formulation development can begin with as little as 1.5 kg of material, and the same equipment can then support everything from very small clinical batches to large commercial runs, enabled by a design that allows the system to switch between continuous blenders of different sizes. The installation will also be contained to 1 µg/m³ to accommodate highly potent compounds. "Hovione will be the first company in the world to offer the ConsiGma® CDC Flex, bringing this next-generation technology with unprecedented flexibility, simplicity and cost-efficiency in continuous tableting," said Marco Gil and António Almeida, co-CEOs, Hovione, said in a press release. "This investment also advances our strategy of building integrated capabilities close to customers in key markets. By adding this new line at East Windsor, we are broadening access to this technology in the U.S. and giving customers a more direct and accelerated path for developing and commercializing complex oral medicines." What Does a Single Development-To-Commercial Line Change? For formulators and process engineers, the most consequential claim is the removal of traditional scale-up. Moving a process from development equipment to commercial equipment typically requires engineering runs, bridging work, and consumption of scarce API, all of which weigh heavily on early programs with limited material. "Installing the CDC Flex at 89 Twin Rivers makes continuous tableting part of an integrated US development and manufacturing workflow," said David Basile, Vice President of Technical Operations, Hovione, in the press release. "Customers can move from formulation and particle engineering to commercial tablets with one Hovione team and one quality system, eliminating traditional scale-up while gaining greater production flexibility, process control and supply continuity." Co-locating spray drying and tableting is also significant because amorphous solid dispersions remain a primary solubility-enhancement route for poorly soluble molecules, and transferring intermediates between sites or vendors adds technology transfer and comparability burdens. The new line builds on the company's earlier US expansion; Hovione recently completed a $100 million investment to bolster US capacity in particle design, amorphous solid dispersions via spray drying, and batch and continuous tableting. How Is the Regulatory Environment Shaping Continuous Tableting Adoption? The company points to the 2022 adoption of ICH Q13, which provides harmonized guidance for continuous manufacturing of drug substances and drug products across the US, Europe, and Japan. Hovione reports that, as of 2024, FDA alone had approved 17 products manufactured under the guidance. Speaking on ICH Q13, FDA's Kelley Burridge, PhD, "Perceived barriers to continuous manufacturing have been falling one by one," and noted an FDA publication showing faster approval times for products with continuous manufacturing elements than for comparable batch products. The platform incorporates inline process analytical technology and automated controls for real-time quality monitoring, along with SimpleCT, an automation and control suite intended to support a single process from development through commercial supply. For sponsors weighing supply resilience and regional sourcing, the East Windsor installation extends a capability that Hovione says only it currently offers as a contract development and manufacturing organization.   Read the full article at PharmTech.com  

Press Clipping
PharmTech, 5 October 2026

Can Continuous Tableting End Scale-Up for Complex Oral Drugs?

Oct 05, 2026

Formulation Development/Drug Product Manufacturing  Hovione Completes $46-M Tablet Mfg Facility Expansion  Hovione, a CDMO of drug substances and drug products, has completed an expansion of its tablet development and manufacturing center at its main global campus in Loures, Portugal, adding 25% more commercial-scale batch tableting capacity for oral solid dosage products. The expansion strengthens integrated manufacture of amorphous solid dispersions by spray drying and tableting at a single site. The recently inaugurated expansion completes an investment cycle of more than EUR 40 million ($46 million).  Hovione expanded its batch tableting capacity by adding an additional line mirroring the original unit across every local operation: dispensing, blending, dry granulation, tableting, and film coating. The mirrored configuration reinforces capacity at the 300 kg to 400 kg batch scale and provides both redundancy and like-for-like product transfers between lines. Supporting areas, including in-process control and staging space sized to the increased production capacity, were also added as part of the expansion.  Read the full article at DCATVCI.org  

Press Clipping
DCAT Value Chain Insights, 3 September 2026

Supplier News: Lonza, Evonik, Hovione, Catalent & More

Sep 03, 2026

The company is building out more than 200,000 square feet of space in New Jersey. In April, Contract Pharma had the opportunity to tour Hovione’s expanded manufacturing facility in East Windsor, NJ. The company is planning a formal ribbon-cutting this fall; before that, we got an inside look at some new features. Having established United States operations in 2002, Hovione now has more than 200,000 square feet of space in New Jersey. This will be developed into a large, integrated campus in the next five to ten years. Overall, the company’s recent NJ expansion, which began in 2025, has tripled its total spray-drying capacity in the U.S. Future Facility Upgrades A 125,000-square-foot greenfield acquired by Hovione at the East Windsor campus will eventually be a large-scale production site. This includes enhanced quality control and R&D capabilities. Together, all this adds to Hovione’s stable of manufacturing sites, R&D centers, and other offices spread across three continents. Key to the expansion is a targeted reduction of Hovione’s carbon footprint by 40% by the year 2030. Part of this goal is embracing new and/or changing solvent types to help meet sustainability standards. Additionally, the company says automation that has been put in place at its Portugal site will be replicated in NJ. Hovione Aligns NJ Operations At the Drug, Chemical & Associated Technologies Association (DCAT) Week in New York in March, Contract Pharma met with Hovione. There, David Basile, Vice President of Technical Operations—Americas, further illustrated the New Jersey expansion. “Hovione aims to build an equivalent manufacturing network, where clients can go to any site across the globe,” Basile said. “The design of the facility has been well-thought through with material flows [and] gravity-fed processes. It’s scalable. We call each one of these building segments a finger. You can copy and paste these fingers, and they are built to house both spray drying and drug product assets.” Ultimately, with these moves and a strategic partnership model, Hovione aims to provide customers an opportunity to co-invest and access the company’s proprietary knowledge and assets to accelerate programs and create long-term value. Read the full article at ContractPharma.com    

Press Clipping
Contract Pharma, 31 July 2026

Hovione Planning Ribbon-Cutting at NJ Facility – A Behind-the-Scenes Preview

Jul 31, 2026

Also in Events

See All